Q-omics provides the consensus-scored MIR4261 profile across patient tissues and cancer cell-line models. MIR4261 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR4261 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, MIR4261 RNA expression shows 10,756 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight CESC, BRCA, and LIHC as cancer lineages where MIR4261 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4261 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4261 survival associations across molecular data types. MIR4261 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4261 RNA expression–survival associations across cancer types. High MIR4261 expression shows unfavorable associations in CESC, COAD, MESO, LIHC, THYM and LGG. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR4261 RNA expression.
This table summarizes MIR4261 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4261. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4261 shows higher tumor expression in BRCA, STAD, HNSC, PAAD, LUSC and LUAD. The BRCA box plot shows higher MIR4261 RNA expression in tumor versus normal tissue (log2 FC = +0.532, t-test p < 0.001).
This table shows molecular features associated with MIR4261 in patient tissues and cancer cell lines. In patient samples, MIR4261 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
